APM
Aptorum Group Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$8.26
−14.84%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +100.0%
- EBIT
- +100.0%
- EPS
- +54.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +51.6%
- EBIT
- +52.1%
- Net income
- +68.1%
- EPS
- +75.6%
- Free cash flow
- -54.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026